(Q38010486)

26 August 2017

title

Lung transplant infection (English)

1 reference

26 August 2017

1 reference

Sergio R Burguete

1

1 reference

26 August 2017

Diego J Maselli

series ordinal

2

1 reference

26 August 2017

Juan F Fernandez

series ordinal

3

1 reference

26 August 2017

Stephanie M Levine

series ordinal

4

1 reference

26 August 2017

publication date

1 January 2013

1 reference

26 August 2017

1 reference

26 August 2017

volume

18

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

22-38

1 reference

Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Epidemiology and management of infections after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Pulmonary infection defense after lung transplantation: does airway ischemia play a role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Anastomotic airway complications after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Current trends in immunosuppression for lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Conventional and novel approaches to immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Use of cyclosporine in lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Rapamycin in transplantation: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Corticosteroid effects on cell signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Basiliximab in lung transplantation: preliminary experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

The impact of induction on survival after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Basiliximab as an alternative to antithymocyte globulin for early immunosuppression in lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Five-year outcomes with alemtuzumab induction after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Bacterial and fungal pneumonias after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Survival of Burkholderia cepacia sepsis following lung transplantation in recipients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Bacterial colonization of the donor lower airways is a predictor of poor outcome in lung transplantation☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

A review of lung transplant donor acceptability criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Impact of donor lung organisms on post-lung transplant pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

A positive donor gram stain does not predict outcome following lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Native lung complications in single-lung transplant recipients and the role of pneumonectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Invasive pneumococcal infections in adult lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Cytomegalovirus and lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

An international survey of cytomegalovirus management practices in lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Guidance on novel influenza A/H1N1 in solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

The novel 2009 H1N1 influenza virus pandemic: unique considerations for programs in cardiothoracic transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Common infections in the lung transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Viral infections in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Incidence and morbidity of human metapneumovirus and other community-acquired respiratory viruses in lung transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Fungal infections after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Assessment of infection risks prior to lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Infections after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Antifungal prophylaxis in lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Aspergillus infections in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Fungi and molds following lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Fungal infections after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Approach to the diagnosis of invasive aspergillosis and candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Posttransplantation disseminated coccidioidomycosis acquired from donor lungs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Fungal infections in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Mucormycosis of the bronchial anastomosis: a case of successful medical treatment and historic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

A survey of anti-fungal management in lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Feasibility, tolerability, and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Safety of aerosolized amphotericin B lipid complex in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Mycobacterium abscessus chest wall and pulmonary infection in a cystic fibrosis lung transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Mycobacterium abscessus infections in lung transplant recipients: the international experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Airway complications and management after lung transplantation: ischemia, dehiscence, and stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Aspergillus infections in lung transplant recipients: risk factors and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Antimicrobial prophylaxis regimens following transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

21 January 2018

Pneumocystis pneumonia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Nocardia infection in lung transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Pulmonary nocardiosis: risk factors, clinical features, diagnosis and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Long-term azithromycin therapy for bronchiolitis obliterans syndrome: divide and conquer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Chlamydia pneumoniae infection after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Infections in lung allograft recipients: ganciclovir era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Donor-to-host transmission of bacterial and fungal infections in lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

A Prospective Molecular Surveillance Study Evaluating the Clinical Impact of Community-Acquired Respiratory Viruses in Lung Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

Voriconazole Prophylaxis in Lung Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2012.02196.X

A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group

21 January 2018

1 reference

12 December 2020

Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents

1 reference

12 December 2020

Cryptococcosis in solid organ transplant recipients

1 reference

12 December 2020

Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients

1 reference

12 December 2020

The impact of invasive fungal diseases on survival after lung transplantation

1 reference

12 December 2020

Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome

1 reference

12 December 2020

Aspergillus Galactomannan Antigen in the Bronchoalveolar Lavage Fluid for the Diagnosis of Invasive Aspergillosis in Lung Transplant Recipients

1 reference

12 December 2020

Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab

1 reference

12 December 2020

Bronchiolitis obliterans syndrome development in lung transplantation patients

1 reference

12 December 2020

Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation

1 reference

12 December 2020

Screening of donor and recipient prior to solid organ transplantation

1 reference

12 December 2020

Risk/benefit ratio of perioperative OKT3 in cardiac transplantation

1 reference

12 December 2020

Impact ofBurkholderiaInfection on Lung Transplantation in Cystic Fibrosis

1 reference

12 December 2020

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

1 reference

12 December 2020

Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome

1 reference

12 December 2020

Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres

1 reference

12 December 2020

Anastomotic infections in lung transplant recipients

1 reference

12 December 2020

Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management

1 reference

12 December 2020

Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection

1 reference

12 December 2020

Risk factors for early, cumulative, and fatal infections after heart transplantation: a multiinstitutional study.

1 reference

12 December 2020

Airway epithelium of transplanted lungs with and without direct bronchial artery revascularization

1 reference

12 December 2020

Risk factors for ICU-acquired pneumonia

1 reference

12 December 2020

Immunosuppression for lung transplantation

1 reference

12 December 2020

The spectrum of mycobacterial infection after lung transplantation

1 reference

12 December 2020

Invasive aspergillosis in solid organ transplant recipients

1 reference

12 December 2020

Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome

1 reference

12 December 2020

Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis

1 reference

12 December 2020

Tuberculosis in transplanted lungs.

1 reference

12 December 2020

Cytomegalovirus in solid organ transplant recipients

1 reference

12 December 2020

Bronchial transsection and reanastomosis in pigs with and without bronchial arterial circulation

1 reference

12 December 2020

Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group

1 reference

12 December 2020

Respiratory viral infections in transplant recipients

1 reference

12 December 2020

RNA respiratory viral infections in solid organ transplant recipients

1 reference

12 December 2020

Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex

1 reference

12 December 2020

Candida in solid organ transplant recipients

1 reference

12 December 2020

Pneumonia and influenza death rates--United States, 1979-1994

1 reference

12 December 2020

Pre-emptive therapy with azoles in lung transplant patients

1 reference

12 December 2020

Effect of nasogastric tubes on the nose and maxillary sinus

1 reference

12 December 2020

Early and late infections in lung transplantation patients

1 reference

12 December 2020

RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection

1 reference

12 December 2020

Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria

1 reference

12 December 2020

10.1111/J.1440-1843.2012.02196.X

Identifiers

DOI

1 reference

26 August 2017

0 references

1 reference